Product image of Lenalidomid Avansor (Lenalidomide) supplied by GNH India

Lenalidomid Avansor

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomid Avansor (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomid Avansor, is an immunomodulatory drug presented as an oral formulation for systemic use. It is employed in the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma, in adult patients. The medication works by modifying the immune system and inhibiting tumor growth pathways.

GNH India supplies Lenalidomid Avansor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across regions.

Manufacturer / TM Owner

Avansor Pharma Oy

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenalidomide is used in hematologic malignancies that involve abnormal plasma or lymphoid cells.

  • Multiple Myeloma: improves progression‑free survival and overall response rates in adult patients.
  • Myelodysplastic Syndromes: reduces transfusion dependence and delays transformation to acute leukemia.
  • Mantle Cell Lymphoma: contributes to disease control when combined with other therapies.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering its substrate specificity. This triggers ubiquitination and proteasomal degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), leading to reduced survival signals for malignant cells, enhanced T‑cell and NK‑cell mediated immunity, and inhibition of angiogenesis within the tumor microenvironment.

Side Effects

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Fatigue: feeling of tiredness or lack of energy.
  • Nausea: upset stomach with possible vomiting.
  • Diarrhea: loose stools occurring intermittently.
  • Rash: mild skin irritation or redness.

Serious or Rare Side Effects

  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Severe neutropenia: markedly reduced neutrophil count increasing infection risk.
  • Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

Precautions & Warnings

Before initiating Lenalidomid Avansor, several safety considerations should be reviewed.

  • Pregnancy risk: contraindicated in pregnancy (Category X); effective contraception required.
  • Thromboembolism risk: assess patient history and consider prophylactic anticoagulation.
  • Renal function: dose may need adjustment in severe impairment.
  • Hematologic monitoring: regular CBC to detect neutropenia or anemia.
  • Drug interactions: review concomitant medications for CYP or immunosuppressive agents.
  • Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and light.

Avoid Interactions

Lenalidomid Avansor can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce plasma concentrations of lenalidomide.
  • Anticoagulants (e.g., warfarin, direct oral anticoagulants): increased risk of thrombotic or bleeding complications; close monitoring required.

Moderate Interactions (Monitor Closely)

  • Immunosuppressants (e.g., cyclosporine, tacrolimus): may enhance immunosuppressive effects, increasing infection risk.
  • Vaccines (live attenuated): reduced efficacy; avoid administration during therapy.
  • Other antineoplastic agents: overlapping toxicities such as myelosuppression; adjust dosing as needed.

Frequently Asked Questions

Lenalidomid Avansor contains lenalidomide, which is indicated for the treatment of adult patients with multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma. These are hematologic cancers where the drug helps control disease progression and improve response rates.

Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, causing selective degradation of transcription factors Ikaros and Aiolos. This action reduces survival signals in malignant cells, enhances immune‑mediated tumor killing, and inhibits new blood‑vessel formation that supports cancer growth.

The dosage of Lenalidomid Avansor is individualized by the prescribing clinician based on the specific indication, disease stage, renal function and other patient factors. Only a qualified healthcare professional should determine the appropriate dose and schedule.

Lenalidomid Avansor is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception, and breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomid Avansor belongs to the immunomodulatory drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It is often used in combination regimens and may provide benefits in patients who have progressed on or are unsuitable for alternative therapies.

Store Lenalidomid Avansor at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and avoid storing in areas with high humidity or temperature fluctuations.

Lenalidomid Avansor is taken orally, usually with or without food as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia that can predispose to infections, and the potential development of secondary primary malignancies. Patients should be monitored closely for these complications.

Lenalidomid Avansor should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled severe renal impairment unless dose adjustments are made. Clinicians must evaluate each patient’s medical history before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT